Search results
Found 15 matches for
Innovation at the MRC WIMM
17 February 2025
Here at the MRC Weatherall Institute of Molecular Medicine, we foster a strong culture of innovation.
35 Years of the MRC WIMM
23 October 2024
In 1989, Sir David Weatherall founded the Institute of Molecular Medicine to bridge the gap between basic science and clinical medicine. To mark 35 years since the MRC WIMM opened its labs, we're looking back on some of our highlights and achievements.
Yellowstone Biosciences spinout launches to advance cutting-edge cancer therapies
15 July 2024
Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on groundbreaking research from the MRC Weatherall Institute of Molecular Medicine at the University of Oxford.
Professor Simon Davis appointed as RDM’s first Entrepreneurship Lead
5 October 2023
Simon Davis, Professor of Molecular Immunology in the MRC TIDU at the MRC WIMM, has been appointed as RDM’s first Entrepreneurship Lead.
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing
19 October 2022
The biotechnology company builds upon research conducted by Professor Jim Hughes and Prof. James Davies at the MRC Weatherall Institute of Molecular Medicine, and combines 3D genome technology and machine learning to decode the dark matter of the human genome.
Biotech spinout MiroBio acquired by Gilead Sciences for ~£332m
5 August 2022
Co-founded by Prof. Simon Davis, MiroBio focuses on developing therapeutics for inflammatory diseases.
Novel all-in-one vaccine developed to tackle future coronavirus threats
6 July 2022
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
Spin-out company Alethiomics launches
15 December 2021
The enterprise will focus on developing targeted therapies for a specific family of blood cancers.
DNA breakthrough could help identify why some people are more affected by Covid-19
10 June 2021
Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.
Promising therapy for common form of eczema identified in early-stage trial
23 October 2019
A therapy that targets the immune system showed promise for treating atopic dermatitis – the most common form of eczema – in a small proof-of-concept trial, led by scientists from the MRC HIU.
MiroBio launches with £27m from leading life sciences investors
11 October 2019
New Oxford start-up is established to develop novel therapeutics based on the expertise of the Davis and Cornall groups at MRC HIU.
Spinout co-founded by WIMM computational biologist launches new software
5 May 2016
In the summer of 2014, Steve Taylor (Head of the Computational Biology Research Group at the MRC WIMM) was awarded £27,000 by the Oxford Invention Fund to build Zegami, a high throughput image analysis tool.
Oxford spin-out Orbit Discovery launches peptide-discovery platform
26 January 2016
Orbit Discovery – a new spinout from the University of Oxford – has raised seed funding to commercialise technology which will help to identify targeted, affordable therapeutic drugs known as peptides.
WIMM PhD students reach the final of international biotech startup competition
11 May 2015
Bridging the divide between academia and industry is the sacred goal of many researchers, but few are equipped to take their ideas from the bench to the boardroom.